Trial reportJournal of clinical hypertension (Greenwich, Conn.)2004
Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Eplerenone for hypertension.The Cochrane database of systematic reviews · 2017Pooled it
- Esaxerenone versus angiotensin II receptor blockers as second-line therapy in older Japanese patients with uncontrolled hypertension on calcium channel blockers: the randomized, open-label ESCORT-HT study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Trial
- Effects of eplerenone on blood pressure and glucose metabolism in Japanese hypertensives with overweight or obesity.Medicine · 2019Trial
- Age-stratified efficacy and safety of esaxerenone versus angiotensin II receptor blockers in older patients with hypertension: a predefined subanalysis of the ESCORT-HT study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- ACE Inhibition to Distinguish Low-Renin Hypertension From Primary Aldosteronism.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Rationale and Design of a Randomized, Open-Label, Parallel-Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT-HT).Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2023Article
- Efficacy of esaxerenone-a nonsteroidal mineralocorticoid receptor blocker-on nocturnal hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.Vascular health and risk management · 2018Article
- Renal denervation in hypertensive patients not on blood pressure lowering drugs.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Review
- Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.Journal of human hypertension · 2010Article
- Aldosterone and arterial hypertension.Nature reviews. Endocrinology · 2010Review
- Hypertension in Asian/Pacific Island Americans.Journal of clinical hypertension (Greenwich, Conn.) · 2009Review
- Evolution of diagnostic criteria for primary aldosteronism: why is it more common in "drug-resistant" hypertension today?Current hypertension reports · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 40% of Japanese patients with essential hypertension, including low-renin hypertension, are inadequately managed. Low-renin hypertension generally responds poorly to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, but may respond more optimally to diuretics, calcium channel blockers, and aldosterone blockers. This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study evaluated the efficacy and safety of the selective aldosterone blocker eplerenone in 193 Japanese patients with essential hypertension. Although not a study inclusion criterion, baseline active plasma renin levels were consistently low (5.7-10.1 mU/L); most patients met the criteria for low-renin hypertension (< or =42.5 mU/L; normal range, 7-76 mU/L). Patients received placebo or eplerenone 50, 100, or 200 mg once daily for 8 weeks. Systolic blood pressure decreased significantly (-6.8 to -10.6 mm Hg vs. -2.1 mm Hg; p< or =0.0022 vs. placebo). Eplerenone offers significant blood pressure reduction with good tolerability in Japanese patients with hypertension, including those with low-renin hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.